HC Wainwright Reiterates Buy Rating for AnaptysBio (NASDAQ:ANAB)

AnaptysBio (NASDAQ:ANAB – Get Free Report)‘s stock had its “buy” rating reissued by HC Wainwright in a research note issued to investors on Tuesday, Benzinga reports. They currently have a $55.00 price target on the biotechnology company’s stock. HC Wainwright’s target price indicates a potential upside of 74.38% from the company’s current price. Other equities […]

Leave a Reply

Your email address will not be published.

Previous post Air Products and Chemicals (NYSE:APD) Price Target Raised to $295.00
Next post Alignment Healthcare (NASDAQ:ALHC) Rating Reiterated by Piper Sandler